-
Shanghai Junshi Biosciences Partners with Zein Biotechnology for PCSK9 mAb Commercialization in China
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with compatriot firm Zein Biotechnology to collaborate on the commercialization of its PCSK9 monoclonal antibody (mAb), ongericimab (JS002), in mainland China. The financial details of the agreement have not been disclosed. Regulatory Filings and Phase III…
-
MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline
•
US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results for the second quarter of 2023, showing a 7% year-on-year (YOY) growth in worldwide sales, reaching USD 15 billion in constant exchange rates. The pharmaceuticals business reached USD 13.457 billion, up 8% YOY, while Animal…
-
GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs
•
GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced the successful completion of a $22 million A+ round financing. Since its inception in March 2021, the company has raised nearly $90 million in total funding. This latest round was led by existing investor Qiming…
-
GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer
•
GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has granted market approval for its programmed death-1 (PD-1) inhibitor, Jemperli (dostarlimab), as a first-line treatment for advanced or recurrent endometrial cancer. This indication is for patients who are to first…
-
Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna
•
US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca’s originator product Symbicort. This approval positions Viatris as the first company to offer an…
-
Mindray Bio-Medical Electronics to Acquire Majority Stake in DiaSys Diagnostic Systems
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical device company based in China, is poised to acquire a 75% controlling stake in Germany-headquartered in vitro diagnostics (IVD) specialist DiaSys Diagnostic Systems GmbH. The transaction is valued at EUR 115 million (USD 127 million), marking a significant move…
-
EnChannel Secures RMB 200 Million in Series A Funding to Advance Electrophysiology Solutions
•
EnChannel Medical, a Guangzhou-based electrophysiology platform company, has reportedly secured RMB 200 million (USD 28 million) in a Series A financing round. The round was co-led by Lapam Capital and Lilly Asia Ventures, with the proceeds earmarked for enhancing clinical filings, commercialization efforts, and research and development systems within the…
-
Sinovation Secures Over RMB 100 Million in Series D+ Financing for Neurosurgery Innovations
•
Beijing-based Sinovation (Beijing) Medical Technology Co., Ltd., a leader in neurosurgery diagnosis, minimally invasive procedure treatment, and smart industry platform, has reportedly raised over RMB 100 million (USD 14 million) in a Series D+ financing round. The round saw participation from notable investors such as Xinda Kunpeng Investment, Tsing Ventures,…
